| Project/Area Number |
18591016
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
SHIMOSAWA Tatsuo The University of Tokyo, Faculty of Medicine, Lecturer (90231365)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ANDO Katsuyuki The University of Tokyo, Faculty of Medicine, Associate Professor (60184313)
MIYAMOTO Yusei The University of Tokyo, Dept of Integrated Biosciences, Professor (60157691)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥4,010,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2006: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | Oxidative stress / platinum / Metabolic syndrome / renal injury / safety / vascular damage / insulin resistance / アドレノメデュリン / 催奇形性 |
|---|
| Research Abstract |
In the present study, we revealed the therapeutic potency of platinum nanoparticle in dB/dB mouse loaded with angiotensin II and salt loaded model, aged adrenomedullin knockout mouse, and cisplatinum-induced renal failure mouse model. These models are related with metabolic syndrome and vascular damage in dB/dB mouse was remarkably reversed by platinum. Also aged-adrenomedullin knockout mouse reversed its insulin resistance when platinum is administered for 3 month but not for 1 month. Platinum showed its safety by reversing cis-platinum-induced nephrotoxicity and its main role was inhibiting ROS production. To investigate platinum safety we examined its effects on immunity, teratogeniety and tissue accumulation. Neither examination revealed toxicity. To improve its bioavailability and further investigation in human will lead us to new therapeutic approach in metabolic syndromes and its related organ damages.
|
